These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30410293)

  • 1. Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study.
    Pearce C; Islam N; Bryce R; McNair ED
    Int J Angiol; 2018 Dec; 27(4):213-222. PubMed ID: 30410293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention.
    McNair ED; Wells CR; Mabood Qureshi A; Basran R; Pearce C; Orvold J; Devilliers J; Prasad K
    Clin Cardiol; 2010 Nov; 33(11):678-85. PubMed ID: 21089112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents.
    Park HJ; Seo SM; Shin WS; Kim HY; Choi YS; Koh YS; Youn SG; Park MW; Chang K; Kim PJ; Jung HO; Baek SH; Chung WS; Seung KB; Yoo KD
    Coron Artery Dis; 2011 Jan; 22(1):12-7. PubMed ID: 21197704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study).
    Spadaccio C; Patti G; De Marco F; Coccia R; Di Domenico F; Pollari F; Zanzonico R; Pettinari M; Lusini M; Di Sciascio G; Covino E; Chello M
    Am J Cardiol; 2013 Jul; 112(1):21-6. PubMed ID: 23561587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.
    Rathore S; Kinoshita Y; Terashima M; Katoh O; Matsuo H; Tanaka N; Kimura M; Tsuchikane E; Nasu K; Ehara M; Asakura K; Asakura Y; Suzuki T
    EuroIntervention; 2010 Feb; 5(7):841-6. PubMed ID: 20142201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute coronary syndrome - a frequent clinical manifestation of bare metal in-stent restenosis.
    Drozd J; Wójcik J; Małek R; Korona B; Zapolski T; Wysokiński A
    Kardiol Pol; 2010 Jun; 68(6):637-45. PubMed ID: 20806192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a bare-metal stent still useful for improving the outcome of percutaneous coronary intervention? From the FU-Registry.
    Gondo K; Ike A; Ogawa M; Shirai K; Sugihara M; Nishikawa H; Iwata A; Kawamura A; Mori K; Zhang B; Miura S; Yasunaga S; Saku K
    J Cardiol; 2017 Apr; 69(4):652-659. PubMed ID: 27492658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of interleukin-6-572C/G promoter polymorphism and serum levels to post-percutaneous coronary intervention restenosis.
    Gao J; Liu Y; Cui RZ; Mao YM; Zhou J; Chen Q; Zhao FM; Yang GM
    Chin Med J (Engl); 2013 Mar; 126(6):1019-25. PubMed ID: 23506572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with intra-stent restenosis after percutaneous coronary intervention.
    Alexandrescu DM; Mitu O; Costache II; Macovei L; Mitu I; Alexandrescu A; Georgescu CA
    Exp Ther Med; 2021 Oct; 22(4):1141. PubMed ID: 34504587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of drug-eluting balloon in patients with bare-metal or drug-eluting stent restenosis.
    Berta B; Jambrik Z; Kohar K; Szabo G; Ruzsa Z; Molnar L; Barczi G; Geller L; Becker D; Merkely B
    Hellenic J Cardiol; 2014; 55(5):369-77. PubMed ID: 25243435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.
    Nishihira K; Shibata Y; Ishikawa T; Nomura K; Nakama T; Mine D; Inoue Y; Ashikaga K; Kuriyama N; Matsuyama A; Imamura T; Asada Y; Kitamura K
    Circ J; 2010 Nov; 74(11):2329-33. PubMed ID: 20890050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.
    Abizaid A; Costa JR; Banning A; Bartorelli AL; Dzavik V; Ellis S; Gao R; Holmes DR; Jeong MH; Legrand V; Neumann FJ; Nyakern M; Orlick A; Spaulding C; Worthley S; Urban PM;
    JACC Cardiovasc Interv; 2012 Jan; 5(1):64-71. PubMed ID: 22230152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
    Ramsdale DR; Rao A; Asghar O; Ramsdale KA; McKay E
    J Invasive Cardiol; 2008 Oct; 20(10):493-500. PubMed ID: 18829991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherosclerosis and the Hypercholesterolemic AGE-RAGE Axis.
    McNair E; Qureshi M; Prasad K; Pearce C
    Int J Angiol; 2016 Jun; 25(2):110-6. PubMed ID: 27231427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.